These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23689766)

  • 41. [Torsade de pointes: a severe and unknown adverse effect in a patient taking methadone].
    Vodoz JF; Jaquier F; Lamy O
    Praxis (Bern 1994); 2003 Oct; 92(41):1748-50. PubMed ID: 14587370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.
    Shao H; Shi D; Dai Y
    Br J Clin Pharmacol; 2023 Apr; 89(4):1386-1392. PubMed ID: 36346345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug-Induced QTc Prolongation: What We Know and Where We Are Going.
    Mangona E; Sandonato E; Brothers TN; Pawasauskas J
    Curr Drug Saf; 2022; 17(2):100-113. PubMed ID: 34551700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reply to Cataldo (2016): Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
    Kao D; Haigney MC; Mehler PS; Krantz M
    Addiction; 2016 Sep; 111(9):1686-7. PubMed ID: 27273759
    [No Abstract]   [Full Text] [Related]  

  • 46. Cocaine-related torsade de pointes in a methadone maintenance patient.
    Krantz MJ; Rowan SB; Mehler PS
    J Addict Dis; 2005; 24(1):53-60. PubMed ID: 15774410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
    Glassman AH; Bigger JT
    Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physician awareness of the cardiac effects of methadone: results of a national survey.
    Krantz MJ; Rowan SB; Schmittner J; Bucher Bartelson B
    J Addict Dis; 2007; 26(4):79-85. PubMed ID: 18032235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long QTc interval and torsade de pointes caused by fluconazole.
    Pham CP; de Feiter PW; van der Kuy PH; van Mook WN
    Ann Pharmacother; 2006; 40(7-8):1456-61. PubMed ID: 16849620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.
    Hohnloser SH; Klingenheben T; Singh BN
    Ann Intern Med; 1994 Oct; 121(7):529-35. PubMed ID: 8067651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
    Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
    Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methadone-induced long QT syndrome vs methadone-induced torsades de pointes.
    Justo D
    Arch Intern Med; 2006 Nov; 166(20):2288; author reply 2289-90. PubMed ID: 17101953
    [No Abstract]   [Full Text] [Related]  

  • 57. Cardiovascular toxicity induced by SSRIs: Analysis of spontaneous reports submitted to FAERS.
    Chen Y; Fan Q; Liu Y; Shi Y; Luo H
    Psychiatry Res; 2023 Aug; 326():115300. PubMed ID: 37364503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450].
    Hrovatin E; Zardo F; Brieda M; Dametto E; Piazza R; Antonini-Canterin F; Cassin M; Meneguzzo N; Viel E; Lestuzzi C; Di Gennaro G; Nicolosi GL
    Ital Heart J Suppl; 2004 Sep; 5(9):735-40. PubMed ID: 15568612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.